NSCLC Education
NSCLC treatment requires navigating an expanding array of targeted therapies, immunotherapy combinations, and biomarker-driven strategies. Knowledge Med sessions use live case simulations to help community providers make confident treatment decisions — from first-line therapy selection to managing acquired resistance.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing non-small cell lung cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Ensuring comprehensive biomarker testing (EGFR, ALK, ROS1, KRAS G12C, PD-L1)
- Selecting first-line therapy based on molecular and PD-L1 status
- Managing acquired resistance to EGFR TKIs and ALK inhibitors
- Integrating perioperative immunotherapy for resectable disease
What Sessions Cover
Knowledge Med NSCLC sessions use interactive case simulations to address these topics and more.
- Biomarker-driven first-line therapy selection in advanced NSCLC
- EGFR-mutant NSCLC: osimertinib and beyond
- KRAS G12C inhibitors and emerging targeted agents
- Perioperative immunotherapy and chemoimmunotherapy strategies
Interactive NSCLC Sessions
Case Simulations
Work through realistic non-small cell lung cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key NSCLC clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a NSCLC Session
Third-party, non-promotional non-small cell lung cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session